archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • News Archive
    Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive CSL Half year Results Announcement for 2008 09 CSL Half year Results Announcement for 2008 09 Melbourne Australia 18 02 2009 CSL Limited today announced its first half result for period ended 31 December 2008 Download this release CSL Half

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1234772848181/prdetail.htm (2014-01-05)
    Open archived version from archive


  • News Archive
    CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive CSL Limited Change of Company Secretary CSL Limited Change of Company Secretary Melbourne Australia 18 01 2009 With immediate effect Mr Edward Bailey is the company secretary of CSL Limited Mr Peter Turvey will continue

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1229961373919/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    News Archive 2003 News Archive 2002 News Archive 2001 News Archive 2000 News Archive 1999 News Archive 13 10 2008 CSL Receives FTC Request for Additional Information CSL Receives FTC Request for Additional Information on its Proposed Merger with Talecris Biotherapeutics More 02 09 2008 CSL Appoints New Director CSL today announced that Mr David Anstice has been appointed a Director of the Company effective 2 September 2008 More 13 08 2008 Full Year Results for 2008 CSL Limited today announced a profit after tax of 702 million for the twelve months ended 30 June 2008 up 30 when compared to the twelve months ended 30 June 2007 On a constant currency basis profit grew 45 More 17 06 2008 CSL Receives TGA Approval to Register Panvax Avian Flu Vaccine CSL Limited announced today that it has received approval from the Australian Therapeutic Goods Administration TGA to register Panvax CSL s avian influenza vaccine Developed by CSL in collaboration with the Australian government Panvax is intended for use in the prevention of influenza caused by a pandemic strain of avian influenza virus More 20 02 2008 CSL Half Year Results Announcement for 2007 08 CSL Limited today announced a profit

    Original URL path: http://www.csl.com.au/newsroom/archive.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    MLC Victorian Minister for Innovation today officially opened the new Biopharmaceutical Formulation Centre located at CSL Limited in Parkville Victoria The Minister also chose the occasion to launch the new Victorian Government Biotechnology Strategy The Centre will be used to formulate quantities of experimental biotechnology medicines under GMP for use in clinical trials and has been part funded by a Science Technology and Innovation STI Infrastructure grant of 2 7 million from the Victorian Government CSL has provided a further 5 3 million as well as additional R D infrastructure and expertise The facilities will be used by CSL for their own development projects by a key partner Swinburne University for the training of students in GMP procedures and to provide a service to small biotechnology companies needing assistance in formulating their own products for testing This is a wonderful example of how the 2004 Victorian Biotechnology Strategy has resulted in a practical initiative which benefits not only a major company like CSL but smaller companies who need their products formulated at cost as well as the academic sector CSL Global Head of R D Dr Andrew Cuthbertson said today CSL will use the facility to formulate experimental biotechnology medicines

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562739911/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    of the world s leading manufacturers of influenza vaccine announced today that the U S Food and Drug Administration FDA has approved its influenza virus vaccine to be known as Afluria in the U S for active immunisation to prevent influenza disease caused by influenza virus types A and B present in the vaccine in adults 18 years and older Today s approval marks CSL s first entry into the U S influenza vaccine market Afluria will be made available in both single dose thiomersal free pre filled syringes and in multidose vials to provide choice and convenience to caregivers who administer it CSL plans to begin delivering shipments to the U S during the 2007 2008 flu season through its subsidiary CSL Biotherapies CSL Biotherapies is the leading producer of influenza vaccine in the Southern Hemisphere and is proud to bring a 40 year heritage in influenza vaccines to the U S market where boosting the supply of available flu vaccine and increasing vaccination rates is a priority public health goal Commencing export of our flu vaccine to the U S will be the next step for us in becoming a significant global player in the supply of this life saving product General Manager of CSL Biotherapies Mary Sontrop said today The World Health Organisation and the Centres for Disease Control and Prevention in the U S agree that globally the need for influenza vaccines greatly exceeds the available supply Although our entry into the U S will initially be modest we aim to have a significant role providing much needed diversity of supply in the next four years she said About CSL Limited Headquartered in Melbourne CSL Limited ASX CSL is a global specialty biopharmaceutical company that develops manufactures and markets products to treat and prevent serious human

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562739773/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive Proposed 3 for 1 Share Split Proposed 3 for 1 Share Split Melbourne Australia 14 09 2007 As previously announced CSL Limited is proposing to subdivide its issued capital on the basis that every one 1 fully paid ordinary share each a Share be subdivided into three 3 fully paid ordinary shares the Share Split and that options and performance rights on issue be adjusted in accordance with the Listing Rules The Share Split is intended to benefit shareholders by increasing the liquidity and affordability to retail investors of the Shares If approval is given at the Annual General Meeting AGM to be held on 17 October 2007 each existing Share will be split into three Shares with effect from 7 00pm Melbourne time on 24 October 2007 and each option and performance right on issue at that time under the company s employee equity plans will be split into three and the exercise price if any will decrease by a factor of three Immediately after the Share Split each shareholder will still hold the same proportion of the Company s

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562739685/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive Full Year Results for 2007 Full Year Results for 2007 Melbourne Australia 22 08 2007 CSL Limited today announced its operating result for the full year ended 30 June 2007 Download the full release Full

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562739593/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    and usage is running at levels not previously achieved in other vaccination programs in this age group In some states the uptake rate has been as high as 80 90 CSL has confirmed that in spite of the greater than expected demand it is able to supply the full needs of the program without difficulty This outstanding result could not have been achieved without the sustained commitment of Federal and State Governments to the program public health physician Dr Jeffrey Hanna said today In addition to the vaccination program in schools for girls aged 12 18 years which commenced in March a program to vaccinate women aged 18 26 through General Practice commenced in all States and Territories in July and will continue until mid 2009 Traditionally it has been difficult to get young people to commit to a course of vaccines in General Practice but the National HPV Human Papillomavirus Vaccination Program has evoked wide interest Rural GP Dr Jenny May commented Young women are highly motivated to take up vaccination and have responded well to the public education campaign GPs are reporting excellent uptake of the vaccine in women aged 18 26 years The vaccination program in combination

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562739368/prdetail.htm (2014-01-05)
    Open archived version from archive